Ozempic Competitors to Watch in 2025

Ozempic is a game-changer for weight loss. It’s not the only product on the market. A number of competitors are lining up to provide their version of GLP-1. These could change the game for weight loss and diabetes management.

Who Is in the Game?

GLP-1 drugs range significantly. A number of competitors are already on the market, and additional experimental products are also on the horizon. Biotech companies have invested heavily to get their share of the $100 billion market. Consider a few examples.

Retatrutide, called Triple G, is likely to be a new option in several years. It works on three hormones than others, potentially producing more weight loss. Its additional benefit over others is glucagon hormone control. That could help increase your body’s energy levels.

VK2735 is another experimental product. It offers a key specific benefit: It works faster than Tirzepatide and Semaglutide. What’s more, it could be available in pill form, which could be more attractive to some who do not want to use an injection. Research indicates people lost as much as 32 pounds in as little as 13 weeks.

Eli Lilly hopes to launch its weight loss pill before the competition. The drug is called orforglipron. It is less expensive and easier to produce. A person takes a daily pill. It slows down digestion and manages blood sugar and insulin levels.

Novo Nordisk is also looking for a way to compete. To do so, it developed CagriSema, a one-time-a-week injection that targets cagrilintide, a hormone that regulates appetite and could lower blood sugar levels. This product mimics the naturally occurring hormone, reducing hunger and blood sugar.

Amgen has a different take. This drug company has created MariTide, a much longer-lasting treatment. Patients may be able to take it just once a month or less often. It would be on specific gut hormones. Its specific benefit is that it encourages the body to burn fat more efficiently.

Any of these weight loss drugs could change the game for patients. The question remains about which one will make it through trials to reach the market.